Maribel Cuello

Maribel Cuello

Auto-generated profile, based on publicly available information

Maribel Cuello

Immunology Department, Finlay Institute, Calle 17 esquina 198 Rpto Siboney, Havana 11600, Cuba

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Canadian Journal of Microbiology
Verified
Journal Article
Closed access
Belkis RomeuBelkis Romeu
Belkis Romeu
EGElyzabeth González
Elyzabeth González
JCJudith del Campo
Judith del Campo
RAReynaldo Acevedo
Reynaldo Acevedo
CZCaridad Zayas
Caridad Zayas
OPOliver Pérez
Oliver Pérez
Mucosal immune responses are an early and important line of defense against pathogens. The current understanding of the mucosal immune system allows us to consider the use of nasal immunization for induction of antigen-specific immune responses at the mucosal surface and the systemic compartment. Mucosal adjuvants are key for developing novel mucosal vaccines and represent 1 approach to improving mucosal and systemic immunity. However, few mucosal vaccine adjuvants are currently approved for human use. Neisseria meningitidis B proteoliposome-derived cochleate (AFCo1 — Adjuvant Finlay Cochleate 1) has been demonstrated to be a potent mucosal adjuvant. The present work demonstrates that intranasal immunization of 3 doses of tetanus toxoid (TT) coadministered with AFCo1 in mice promotes high systemic and mucosal responses. The anti-TT IgG serum titers and the mucosal anti-TT IgA in saliva and vaginal wash were significantly higher than TT alone. The analysis of antibody subclasses showed that intranasal administration of AFCo1 + TT induced not only IgG1 but also IgG2a anti-TT antibodies at levels comparable to those obtained with TT vaccine (vax-TET). These data support the fact that AFCo1 is a potent mucosal adjuvant in nasal immunization to a coadministered protein antigen.

12 April 2006 in Vaccine
Verified
Journal Article
Closed access
MCMaribel Cuello
Maribel Cuello
OCOsmir Cabrera
Osmir Cabrera
JCJudith M. del Campo
Judith M. del Campo
EPElina Parajón
Elina Parajón
FSFranklin Sotolongo
Franklin Sotolongo
OPOliver Pérez
Oliver Pérez

1 July 2011 in Expert Review of Vaccines
Verified
Journal Article
Closed access
OCOsmir Cabrera
Osmir Cabrera
MCMaribel Cuello
Maribel Cuello
MLMiriam Lastre
Miriam Lastre
Belkis RomeuBelkis Romeu
Belkis Romeu
JBJulio Balboa
Julio Balboa
OPOliver Pérez
Oliver Pérez
A 5-day workshop on adjuvant for vaccines was held in Trinidad, Cuba, on the 16-21 May 2010. Organized by the Latin American Association for Immunology and the Cuban Society for Immunology, the workshop attracted more than 60 scientists from different parts of the world. The meeting summarizes current knowledge regarding vaccine adjuvants, including delivery systems and parasitic vaccines. Main discussion topics were the discovery of new adjuvant formulations, action mechanisms for adjuvants, adjuvants for a different route of immunization, focused on mucosal vaccines, and nano- and micro-particles as a delivery system. This article highlights the most important issues presented.